Aprea Therapeutics, Inc. (APRE) has 46 open-market insider trades by 18 insiders since 2019. The most active filer is Oren Gilad, CEO & President.
| Name | Title | Tier | Trades | Value | Last Trade |
|---|---|---|---|---|---|
| Scott M. Rocklage | Dir10% Owner | — | 3 | $24.0M | 2020-06-16 |
| KCIF Co-Investment Fund KB | 10% Owner | — | 1 | $16.7M | 2020-07-07 |
| Redmile Group, LLC via Jeremy Green | 10% Owner | — | 2 | $11.5M | 2020-12-28 |
| 5AM Opportunities I (GP), LLC | — | — | 2 | $9.8M | 2020-10-05 |
| KDev Investments AB | 10% Owner | — | 1 | $6.6M | 2020-04-13 |
| 5AM Ventures IV, L.P. | 10% Owner | — | 1 | $5.0M | 2019-10-07 |
| Johan Christenson | Dir | — | 1 | $4.0M | 2019-10-07 |
| Gregory Alan Korbel | VP | — | 5 | $525K | 2022-07-28 |
| Lars B. Abrahmsen | CSOVP | — | 2 | $369K | 2022-03-10 |
| Bernd R. Seizinger | Dir | — | 4 | $199K | 2026-06-16 |
| Insider | Title | Type | Value | Date |
|---|---|---|---|---|
| John P. Hamill | SrVP/CFO/Prin Fin & Acct Ofcr | Buy | $5K | 2026-01-30 |
| Oren Gilad | President | Buy | $25K | 2026-01-30 |
| Marc Duey | Director | Buy | $25K | 2025-12-10 |
| John P. Hamill | SrVP/CFO/Prin Fin & Acct Ofcr | Buy | $6K | 2025-12-10 |
| Oren Gilad | President | Buy | $10K | 2025-04-03 |
| Oren Gilad | President | Buy | $2K | 2024-10-23 |
Companies that share insiders with APRE, and sector peers with recent insider buying. Related by who files, not by how the stocks move.
| Marc Duey | Director | Sell | $30K | 2024-10-18 |
| Marc Duey | Director | Buy | $132K | 2024-10-16 |
| Oren Gilad | President | Buy | $725 | 2024-10-15 |
| Marc Duey | Director | Buy | $490 | 2024-10-14 |
| Bernd R. Seizinger | Director | Buy | $27K | 2024-10-11 |
| John P. Hamill | SrVP/CFO/Prin Fin & Acct Ofcr | Buy | $123 | 2024-10-11 |
| John P. Hamill | SrVP/CFO/Prin Fin & Acct Ofcr | Buy | $1K | 2024-10-10 |
| Oren Gilad | President | Buy | $3K | 2024-10-10 |
| John B. Henneman III | Director | Buy | $100K | 2024-03-13 |